598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797632579876159488 |
|---|---|
| author | Michael Chisamore Noelly Madeleine Austin Rayford Gro Gausdal David R Micklem Magnus Blø Dina Alzhanova Josephine Amalia Taverna Chia-Nung Hung Rolf A Brekken Claudia Gorcea-Carson Cristina Oliva Nigel McCracken |
| author_facet | Michael Chisamore Noelly Madeleine Austin Rayford Gro Gausdal David R Micklem Magnus Blø Dina Alzhanova Josephine Amalia Taverna Chia-Nung Hung Rolf A Brekken Claudia Gorcea-Carson Cristina Oliva Nigel McCracken |
| author_sort | Michael Chisamore |
| collection | DOAJ |
| first_indexed | 2024-03-11T11:38:54Z |
| format | Article |
| id | doaj.art-b9872825146948ff8bc92c58b8ebd47b |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T11:38:54Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-b9872825146948ff8bc92c58b8ebd47b2023-11-10T09:00:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0598598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)Michael Chisamore0Noelly Madeleine1Austin Rayford2Gro Gausdal3David R Micklem4Magnus Blø5Dina Alzhanova6Josephine Amalia Taverna7Chia-Nung Hung8Rolf A Brekken9Claudia Gorcea-Carson10Cristina Oliva11Nigel McCracken124Merck and Co., Inc., Rahway, NJ, USA12BerGenBio ASA, Bergen, Norway12BerGenBio ASA, Bergen, Norway1BerGenBio ASA, Bergen, Norway1BerGenBio ASA, Bergen, Norway1BerGenBio ASA, Bergen, Norway3University of Texas Southwestern Medical Center, Dallas, TX, USA4University of Texas Health Science Center, San Antonio, TX, USA4University of Texas Health Science Center, San Antonio, TX, USA3University of Texas Southwestern Medical Center, Dallas, TX, USA6BerGenBio Ltd, Oxford, Oxfordshire, UK6BerGenBio Ltd, Oxford, Oxfordshire, UK6BerGenBio Ltd, Oxford, Oxfordshire, UK |
| spellingShingle | Michael Chisamore Noelly Madeleine Austin Rayford Gro Gausdal David R Micklem Magnus Blø Dina Alzhanova Josephine Amalia Taverna Chia-Nung Hung Rolf A Brekken Claudia Gorcea-Carson Cristina Oliva Nigel McCracken 598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571) Journal for ImmunoTherapy of Cancer |
| title | 598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571) |
| title_full | 598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571) |
| title_fullStr | 598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571) |
| title_full_unstemmed | 598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571) |
| title_short | 598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571) |
| title_sort | 598 bemcentinib pembrolizumab show promising efficacy in metastatic nsclc harbouring mutations associated with poor prognosis exploratory sub analysis from the bgbc008 trial nct03184571 |
| work_keys_str_mv | AT michaelchisamore 598bemcentinibpembrolizumabshowpromisingefficacyinmetastaticnsclcharbouringmutationsassociatedwithpoorprognosisexploratorysubanalysisfromthebgbc008trialnct03184571 AT noellymadeleine 598bemcentinibpembrolizumabshowpromisingefficacyinmetastaticnsclcharbouringmutationsassociatedwithpoorprognosisexploratorysubanalysisfromthebgbc008trialnct03184571 AT austinrayford 598bemcentinibpembrolizumabshowpromisingefficacyinmetastaticnsclcharbouringmutationsassociatedwithpoorprognosisexploratorysubanalysisfromthebgbc008trialnct03184571 AT grogausdal 598bemcentinibpembrolizumabshowpromisingefficacyinmetastaticnsclcharbouringmutationsassociatedwithpoorprognosisexploratorysubanalysisfromthebgbc008trialnct03184571 AT davidrmicklem 598bemcentinibpembrolizumabshowpromisingefficacyinmetastaticnsclcharbouringmutationsassociatedwithpoorprognosisexploratorysubanalysisfromthebgbc008trialnct03184571 AT magnusblø 598bemcentinibpembrolizumabshowpromisingefficacyinmetastaticnsclcharbouringmutationsassociatedwithpoorprognosisexploratorysubanalysisfromthebgbc008trialnct03184571 AT dinaalzhanova 598bemcentinibpembrolizumabshowpromisingefficacyinmetastaticnsclcharbouringmutationsassociatedwithpoorprognosisexploratorysubanalysisfromthebgbc008trialnct03184571 AT josephineamaliataverna 598bemcentinibpembrolizumabshowpromisingefficacyinmetastaticnsclcharbouringmutationsassociatedwithpoorprognosisexploratorysubanalysisfromthebgbc008trialnct03184571 AT chianunghung 598bemcentinibpembrolizumabshowpromisingefficacyinmetastaticnsclcharbouringmutationsassociatedwithpoorprognosisexploratorysubanalysisfromthebgbc008trialnct03184571 AT rolfabrekken 598bemcentinibpembrolizumabshowpromisingefficacyinmetastaticnsclcharbouringmutationsassociatedwithpoorprognosisexploratorysubanalysisfromthebgbc008trialnct03184571 AT claudiagorceacarson 598bemcentinibpembrolizumabshowpromisingefficacyinmetastaticnsclcharbouringmutationsassociatedwithpoorprognosisexploratorysubanalysisfromthebgbc008trialnct03184571 AT cristinaoliva 598bemcentinibpembrolizumabshowpromisingefficacyinmetastaticnsclcharbouringmutationsassociatedwithpoorprognosisexploratorysubanalysisfromthebgbc008trialnct03184571 AT nigelmccracken 598bemcentinibpembrolizumabshowpromisingefficacyinmetastaticnsclcharbouringmutationsassociatedwithpoorprognosisexploratorysubanalysisfromthebgbc008trialnct03184571 |